The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician’s choice (TPC) in relapsed small cell lung cancer (SCLC).
 
Taofeek K. Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES; Coherus Biosciences; GenCart; Taobob LLC
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Coherus Biosciences; Daichi; Eisai; Eisai; EMD Serono; Exelixis; G1 Therapeutics; Heat Biologics; Ipsen; Janssen; Jazz Pharmaceuticals; Lilly; MedImmune; Merck; Meryx Pharmaceuticals; Novartis; PharmaMar; Puma Biotechnology; Roche/Genentech; Takeda; Triptych Health Partners; Xcovery
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals; G1 Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Loxo/Lilly (Inst); Merck (Inst); Meryx Pharmaceuticals (Inst); Novartis (Inst); Oncorus (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor) (Inst); OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst); Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen
Other Relationship - EMD Serono; Novartis; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Reflexion Medical
 
Lauren Averett Byers
Honoraria - Clinical Care Options; UpToDate
Consulting or Advisory Role - Abbvie; Amgen; Arrowhead Pharmaceuticals; AstraZeneca; BeiGene; Chugai Pharma; Daiichi Sankyo; Genentech; Jazz Pharmaceuticals; Merck Sharp & Dohme Corp.; Puma Biotechnology
Research Funding - Amgen (Inst); AstraZeneca (Inst); Jazz Pharmaceuticals (Inst)
 
Ying Cheng
No Relationships to Disclose
 
Hidetoshi Hayashi
Honoraria - 3H Clinical Trial; Amgen; AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Janssen; Lilly; Merck; MSD K.K; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Sysmex; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Janssen; Novocure K.K.
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); Ascent Development Services (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol Myers Squibb Company (Inst); Chugai Pharma (Inst); CMIC CO., Ltd. (Inst); Daiichi Sankyo Co., Ltd. (Inst); Eisai (Inst); Eisai (Inst); EPS Holdings (Inst); EPS Holdings (Inst); GlaxoSmithKline K.K. (Inst); IQVIA Services JAPAN K.K (Inst); Janssen (Inst); Kobayashi Pharmaceutical (Inst); Kyowa Kirin Co., Ltd (Inst); Labcorp Drug Development (Inst); Lilly Japan (Inst); Medpace Japan KK (Inst); Merck (Inst); MSD K.K. (Inst); Nippon Boehringer Ingelheim (Inst); Nippon Kayaku (Inst); Novartis (Inst); Otsuka (Inst); Pfizer (Inst); Pfizer (Inst); PRA Health Sciences Inc. (Inst); Sanofi (Inst); Shionogi (Inst); SRL Medisearch Inc. (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Sysmex
 
Luis G. Paz-Ares
Leadership - ALTUM Sequencing; Stab Therapeutics
Stock and Other Ownership Interests - Altum Sequencing; Stab therapeutics
Honoraria - Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; Mirati Therapeutics; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Pharmamar; Regeneron; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; BMS; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Maurice Perol
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Gritstone Bio; IPSEN; Janssen Oncology; Lilly; Merck Sharp & Dohme; Novartis; Novocure; Pfizer; Roche/Genentech; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Merck Sharp & Dohme; Pfizer; Roche; Takeda
Other Relationship - AstraZeneca
 
Jennifer Turner
Employment - Daiichi Sankyo
 
Meng Qian
Employment - Daiichi Sankyo
 
Cecilio Roi Garcia
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - ADC Therapeutics
 
Juliette Godard
Employment - Daiichi Sankyo
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Auron Therapeutics; Bridge Medicines; D2G Oncology; Daiichi Sankyo/UCB Japan; DISCO; Earli; Genentech/Roche; Harpoon Therapeutics; Jazz Pharmaceuticals; Kowa; Merck
Research Funding - Daiichi Sankyo (Inst); Merck (Inst); Roche/Genentech (Inst)